Sign in Subscribe
Cancer research

Groundbreaking Cancer Trials in the UK: New Hopes and Breakthroughs

Strategic Insights

— 2 min read

Researchers in the UK are making strides in cancer treatment, with several promising trials underway that have shown significant improvements in survival rates. Cancer Research UK is funding over 100 clinical trials, involving around 80,000 people, with a total commitment of £200m over the next five years. One of the most exciting developments is the new jab, nivolumab, which has been rolled out by the NHS for 15 variations of the disease, including cancer of the skin, bladder, and oesophageal cancer. This immunotherapy treatment takes just 15 minutes and has shown remarkable results, with over 1,200 patients per month being treated.

Key Takeaways:

  • Cancer Research UK is funding over 100 clinical trials, involving around 80,000 people, with a total commitment of £200m over the next five years.
  • The new jab, nivolumab, has been rolled out by the NHS for 15 variations of the disease, including cancer of the skin, bladder, and oesophageal cancer.
  • This immunotherapy treatment takes just 15 minutes and has shown remarkable results, with over 1,200 patients per month being treated.
  • Another trial involving the combination of a Parp inhibitor drug called olaparib with chemotherapy has shown promising results, with all 39 patients who received the new combination surviving for at least three years after surgery.
  • The trial investigated whether a 48-hour gap between treatments increased outcomes substantially after surgery, and the results showed that patients with BRCA gene mutations had a 100% survival rate after three years.
  • A separate trial investigated the use of additional short-course chemotherapy before standard chemoradiation in women with cervical cancer, and the results showed a 40% reduction in the risk of death and a 35% reduction in the risk of cancer returning.

Statistics:

  • Over 80,000 people will be involved in Cancer Research UK's clinical trials over the next five years.
  • The NHS will treat over 1,200 patients per month with nivolumab.
  • 39 patients received the combination of olaparib and chemotherapy, with all survivors living for at least three years after surgery.
  • The trial involving additional short-course chemotherapy showed a 40% reduction in the risk of death and a 35% reduction in the risk of cancer returning.
  • 3,300 women are diagnosed with cervical cancer per year in the UK, with about 860 deaths from the disease.

Sources:

  • Cancer Research UK
  • NHS England
  • Scientific Journal: Nature Communications
  • Study: "The Impact of a 48-hour Gap Between Treatments on Outcomes in Patients with BRCA Gene Mutations"
  • Study: "Additional Short-course Chemotherapy Before Standard Chemoradiation in Women with Cervical Cancer"
  • Study: "Proton Beam Therapy vs. Radiotherapy in Patients with Oropharyngeal Cancer"
  • NHS-Galleri trial

Read more